Table of Contents
A novel gene therapy has demonstrated remarkable success in reversing vision loss caused by age-related macular degeneration (AMD) in a small, early-stage clinical trial, offering potential hope for millions suffering from this leading cause of blindness. The findings, published today in The New England Journal of Medicine, represent a significant leap forward in the treatment of AMD, moving beyond symptom management towards potential cures.
The trial, conducted between July 2024 and December 2025, focused on patients with geographic atrophy (GA), the advanced “dry” form of AMD that accounts for approximately 90% of cases. Current treatments for AMD primarily address the “wet” form, characterized by abnormal blood vessel growth, leaving limited options for those with GA.
Targeting the Complement System to Restore Vision
The experimental therapy, developed by GenSight Biologics, utilizes an adeno-associated virus (AAV) vector to deliver a gene encoding a modified form of complement factor I (CFI) directly to the retina. The complement system, a crucial part of the immune response, becomes overactive in GA, leading to chronic inflammation and the death of retinal cells.
“The rationale behind this approach is to rebalance the complement cascade, reducing the destructive inflammation that drives geographic atrophy,” explained a senior official involved in the study. The modified CFI protein aims to regulate the complement system more effectively, protecting retinal cells from further damage.
Promising Results in Phase 1/2 Trial
The Phase 1/2 trial involved 15 patients with advanced GA, divided into three dose groups. Participants received a single subretinal injection of the gene therapy. Over a 12-month period, researchers observed a statistically significant reduction in the rate of GA progression in the highest dose group compared to a natural history control group.
Specifically, the area of GA expansion was reduced by an average of 35% in the high-dose group. Furthermore, several patients experienced a measurable improvement in visual acuity, with some reporting the ability to read more lines on an eye chart. “We observed not just stabilization, but actual regression of the disease in some patients, which is unprecedented,” stated one analyst following the release of the data.
Safety Profile and Future Directions
The gene therapy demonstrated a favorable safety profile, with no serious adverse events related to the treatment reported. Mild, transient inflammation was observed in some patients, but was effectively managed with standard corticosteroids.
The researchers emphasize that these are preliminary findings from a small trial. A larger, randomized, controlled Phase 3 trial is already underway, enrolling over 300 patients across multiple sites in the United States and Europe. This trial will further evaluate the efficacy and safety of the gene therapy, and will be crucial for determining its potential for regulatory approval.
“While more research is needed, these results are incredibly encouraging,” said a lead investigator. “This therapy has the potential to fundamentally change the way we treat age-related macular degeneration, offering a real chance to restore vision and improve the quality of life for millions of people.” The team is also exploring the potential of this approach for other retinal diseases driven by complement dysregulation.
